



ASX AND MEDIA RELEASE

Peplin Completes Enrolment in its Final Phase 3 Clinical Trial for PEP005 Gel in AK

EMERYVILLE, California and BRISBANE, Queensland, 19 August 2009: Peplin, Inc. (ASX:PLI) today announced completion of enrolment in its second Phase 3 clinical trial for the use of PEP005 (ingenol mebutate) Gel to treat actinic (solar) keratoses (AK), a common pre-cancerous skin lesion, on non-head treatment areas, which include the trunk and extremities. This completes enrolment in the final of four pivotal trials planned for the submission of the New Drug Application (NDA) for AK.

This second pivotal Phase 3 trial for non-head locations, known as REGION-Ib, enrolled approximately 200 patients. It is designed to replicate the recently completed REGION-I trial and confirm the results of that trial in which PEP005 Gel, 0.05%, demonstrated a total clearance rate across all anatomical non-head locations of 27.4% ($p < 0.0001$), a median lesion reduction of 66.7% ($p < 0.0001$) and statistical significance when compared to vehicle for clearance of AK's on the chest and the especially difficult-to-treat locations, the arm and back of hand. Peplin plans to complete the REGION-Ib trial results in the fourth quarter of this year.

Peplin's Chief Executive Officer, Tom Wiggans said: "A four week enrolment period for our REGION-Ib trial further demonstrates the enthusiasm by physicians and their patients for new AK treatment options, validating the existence of an unsatisfied medical need that PEP005 Gel could fulfill.

"Based on the data we have generated up to this point, we believe PEP005 Gel and its short course of therapy represents an advance in the treatment of a common skin condition, which if left untreated, can progress to squamous cell carcinoma."

REGION-Ib is a randomised, double-blind, vehicle-controlled clinical trial that is being conducted at multiple sites in the US. Patients self-apply the study medication (PEP005 Gel, 0.05%) or vehicle gel for two consecutive days to a 25-cm² treatment area containing four to eight AK lesions. As with previous trials, the primary efficacy endpoint for this pivotal trial will be the complete clearance rate of AK lesions, and the secondary efficacy endpoint will be the partial clearance rate of AK lesions within the treatment area. Peplin will also measure the overall median percent reduction of AK lesions.

In addition to the REGION-Ib trial on non-head locations, Peplin recently completed enrolment in its REGION-IIa and REGION-IIb trials for the treatment of AKs on the face and scalp (head locations). Earlier this year, Peplin also announced the results from its REGION-I trial, the first Phase 3 trial for non-head locations. Peplin will complete its Phase 3 clinical trials for AK by the end of this year and plans to file a New Drug Application in mid-2010 for the treatment of AK lesions on both head and non-head locations.

Further information:

Tom Wiggans
Chief Executive Officer
Tel: +1-510-653 9700
tom.wiggans@peplin.com

Media:

Camilla Myers
Hill & Knowlton
Tel: 02-9286 1248
cmyers@hillandknowlton.com.au

PEPLIN, INC.

6475 Christie Avenue, Emeryville, CA 94608, USA
Tel: +1-510-653 9700 Fax: +1-510-653 9704

Level 3, Tower One, 25 Montpelier Road, Bowen Hills, QLD, 4006, Australia
Tel: +61-7-3250 1200 Fax: +61-7-3250 1299

ABOUT PEPLIN

Peplin is a development stage specialty pharmaceutical company focused on advancing and commercialising innovative medical dermatology products. Peplin is currently developing ingenol mebutate, or PEP005, which is a novel compound derived from the sap of Euphorbia peplus, or E. peplus, a rapidly growing, readily available plant commonly referred to as petty spurge or radium weed. E. peplus has a long history of traditional use for a variety of conditions, including the topical self-treatment of various skin disorders, including skin cancer and pre-cancerous skin lesions. Peplin's lead product candidate is a patient-applied topical Gel containing ingenol mebutate, a compound the use of which Peplin has patented for the treatment of actinic (solar) keratosis, or AK. This product candidate referred to as PEP005 (ingenol mebutate) Gel is currently in Phase 3 clinical trials, having recently completed their first Phase 3, known as REGION-I.

ABOUT AK

Actinic keratoses (AK), also known as solar keratosis or sun spots, is generally considered the most common pre-cancerous skin condition. AK usually appears as small, rough, scaly areas on the face, lips, ears, back of hands, forearms, scalp or neck. If left untreated, AK lesions may progress to a form of skin cancer called squamous cell carcinoma, or SCC. The Lewin Group, Inc., estimates that the total direct costs for AK in the United States was \$1.2 billion in 2004, and in 2002 there were approximately 8.2 million office visits for the treatment of AK. The Lewin Group also estimated that there were 58 million people in the United States living with AK in 2004. According to a May 2006 issue of The Journal of Family Practice, in northern hemisphere populations, 11% to 25% of adults have at least one AK lesion, compared with 40% to 60% of adults in Australia, which has the highest prevalence of AK worldwide.

FORWARD LOOKING STATEMENTS

This press release contains "forward-looking statements" as defined under U.S. federal securities laws, including, but not limited to, Peplin's clinical development plan and timing of clinical trials referred to herein. These forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions. Forward looking statements are based on management's current, preliminary expectations and actual results could differ materially as a result of various risks and uncertainties, including, but not limited to, delays in clinical trials resulting from, among other things, ambiguous or negative interim results, unforeseen safety issues, failure to conduct the clinical trials in accordance with regulatory requirements or clinical protocols, suspension or termination of a clinical trial by the FDA or other regulatory authorities, lack of adequate funding to continue a clinical trial and other important factors disclosed from time to time in Peplin's disclosures to the ASX and in its Form 10 Registration Statement and most recent quarterly report on Form 10-Q filed with the US Securities and Exchange Commission. Forward-looking statements speak only as of the date they were made. No undue reliance should be placed on any forward-looking statements. Such information is subject to change, and we undertake no obligation to update such statements.